Gene therapy proposed to treat depression
By New Scientist,
New Scientist
| 10. 20. 2010
A novel treatment for depression may soon get the go ahead: injecting genes directly into the brain. It would be the first attempt to treat a psychiatric illness with gene therapy.
A gene called p11 is vital for enabling neurons to respond to the neurotransmitter serotonin. A lack of p11 has been shown to lead to depression in humans.
To test whether gene therapy could help, Michael Kaplitt of the Weill Cornell Medical College in New York City and colleagues first demonstrated that mice lacking p11 showed symptoms of depression, failing to respond with the same vitality as healthy mice when exposed to challenges, such as showing decreased effort when having to swim to an island.
Next they injected viruses containing p11 directly into the nucleus accumbens of the mice lacking p11. This part of the brain is where a lack of p11 manifests itself as depression in humans. The team found this reversed the depression in the mice (Science Translational Medicine, DOI: 10.1126/scitranslmed.3001079).
Although the proposal to do the same in humans sounds drastic, Kaplitt points out that a similar...
Related Articles
By Fyodor D. Urnov and Sadik H. Kassim, Nature | 04.21.2026
In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop...
By Miguel Muñoz, Cadena SER | 08.04.2026
"Para ellos, una familia numerosa no solo es una preferencia personal, sino que es una obligación. Creen que tener tantos hijos como sea posible es necesario para evitar un futuro apocalíptico", aseguraba Xavier Orri, periodista y cofundador de Página Internacional...
By Ryan Knutson and Jessica Mendoza, The Journal. | 03.27.2026
Genetically engineered babies are banned in the U.S. But that isn’t stopping Silicon Valley tech titans from trying to make one. In this final installment from The Journal’s investigation into the fringes of the fertility industry, WSJ’s Emily Glazer reports...
By Antonio Regalado, MIT Technology Review | 03.30.2026
After operating in secrecy for years, a startup company called R3 Bio, in Richmond, California, suddenly shared details about its work last week—saying it had raised money to create nonsentient monkey “organ sacks” as an alternative to animal testing.
In...
